Taiho inks exploratory collaboration with Guardant Health

Japanese drugmaker Otsuka (TYO: 4578) subsidiary Taiho Pharmaceutical has announced a collaboration agreement with USA-based Guardant Health (Nasdaq: GH), to discover new biomarker signatures by leveraging Guardant Health’s GuardantINFORM platform for multimodal analysis of real-world data.

This collaboration aims to discover new biomarker signatures with clinical and biological significance for addressing unmet needs in early-stage recurrent cancer, where the presence of microscopic cancer cells remaining in the body after surgery is a cause of recurrence. This collaboration leverages unique multimodal and longitudinal cohorts within GuardantINFORM, including those with minimal residual disease (MRD) testing.

This initiative is expected to support the development of treatments for patients at high risk of recurrence and lead to new and clinically relevant approaches enabling medical interventions at an early stage of cancer. The collaboration has an overarching goal of driving significant progress in overcoming cancer.